NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS | PR Newswire [Video]

• Binding Term Sheet with a leading global pharmaceutical company includes a substantial upfront payment and funding for the Phase 3 study
• Additionally, milestone payments and double-digit royalties on annual net sales
• The transaction is subject to finalization of a definitive agreement, anticipated in Q1 2025

, /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced today that it has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of PrimeC, its proprietary treatment drug for amyotrophic lateral sclerosis (ALS) in certain key territories. NeuroSense would retain full rights to PrimeC in other key territories.

The binding term sheet outlines substantial financial terms from the pharmaceutical company, including:

1. A substantial upfront payment upon signing a definitive agreement,
2. Funding for the Phase 3 clinical trial,
3. Regulatory and net sales milestone payments, and
4. A tiered royalty structure reaching double-digit percentage on annual net sales.

The binding term …